Intra-cellular Therapies v. Alkem Laboratories: CAPLYTA® Patent Dispute Consolidated
Intra-cellular Therapies, Inc. brought a patent infringement action against Alkem Laboratories, Ltd. in the District of New Jersey over generic lumateperone capsules targeting its branded CAPLYTA® franchise. The case was consolidated with seven related civil actions for all pretrial purposes, spanning 589 days before formal closure as a standalone docket.
CAPLYTA® Generic Challenge: Eight ANDA Cases Consolidated in New Jersey
On 29 August 2024, Intra-cellular Therapies, Inc. filed a patent infringement action against Alkem Laboratories, Ltd. in the United States District Court for the District of New Jersey (Case No. 3:24-cv-08845). The suit asserts two patents — US12070459B2 and US11980617B2 — covering CAPLYTA® drug products and challenging Alkem's proposed generic lumateperone capsules in 10.5 mg, 21 mg, and 42 mg strengths, consistent with an ANDA-type pharmaceutical infringement proceeding.
The recorded basis of termination for this docket is 'Case Consolidated.' The docket order reflects a stipulation and order consolidating civil actions 3:24-cv-04264, 3:24-cv-08845, 3:24-cv-08848, 3:24-cv-08850, 3:24-cv-08852, 3:24-cv-08854, 3:24-cv-08855, and 3:24-cv-08856 for all pretrial purposes. This means the Alkem action is now litigated alongside seven other ANDA defendant cases as a unified proceeding rather than as an independent docket.
The consolidation of eight parallel actions — all centring on the same CAPLYTA® patents — suggests a coordinated wave of ANDA filings by multiple generic manufacturers, a pattern typical of high-value branded pharmaceutical franchises facing paragraph IV challenges. The specific terms governing pretrial management, scheduling, and any bellwether arrangements are not disclosed in the available record for this standalone docket.
See Complete Case & Patent Analysis →Filing to Case Consolidated in 589 days
589 days from filing to consolidation order — merged into a multi-defendant ANDA proceeding
US12070459B2 & US11980617B2 — CAPLYTA® lumateperone capsule formulations
Any pharmaceutical company developing, formulating, or planning to market generic lumateperone capsules in the United States should conduct a freedom-to-operate analysis against both US12070459B2 and US11980617B2 before advancing an ANDA filing. With eight defendants already consolidated in New Jersey, the claim construction outcome will bind all parallel challengers — making early FTO assessment and claim mapping essential to managing at-risk launch decisions.
Official order — verbatim text
The consolidation order merges eight related civil actions — all involving CAPLYTA® lumateperone patents — into a single pretrial proceeding. This procedural step reflects the court's management of parallel ANDA challenges and does not constitute a merits ruling on infringement or validity of US12070459B2 or US11980617B2.
Full party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Intra-cellular Therapies, Inc. | Company | /Search in Eureka ↗ |
| Defendant | Alkem Laboratories, Ltd. | Company | /Search in Eureka ↗ |
| Plaintiff counsel | Katelyn O'Reilly | Attorney | Counsel for Intra-cellular Therapies, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Lauren Ruth Malakoff | Attorney | Counsel for Intra-cellular Therapies, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Liza M. Walsh | Attorney | Counsel for Intra-cellular Therapies, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Walsh Pizzi O'Reilly Falanga LLP | Law Firm | Representing Intra-cellular Therapies, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
R&D signals in the lumateperone and CNS drug formulation IP space
Forward-looking patent and R&D intelligence derived from Intra-cellular Therapies' CAPLYTA® IP position and the competitive landscape around lumateperone and atypical antipsychotic formulations.
Intra-cellular Therapies' lumateperone patent estate: breadth and depth
Intra-cellular Therapies has asserted at least two granted US patents covering CAPLYTA® lumateperone formulations across eight ANDA defendants simultaneously. Mapping the full breadth of their lumateperone patent family — including continuations, divisionals, and method-of-treatment claims — reveals the defensive perimeter around this CNS franchise and signals where future exclusivity extensions may be pursued.
Portfolio depth signalFiling trends in atypical antipsychotic capsule formulation patents
The multi-defendant ANDA challenge against CAPLYTA® reflects broader competitive pressure on atypical antipsychotic drug formulations. Tracking recent patent filing trends in lumateperone, related phosphodiesterase inhibitors, and CNS capsule formulation technologies can identify where innovators and generics are building competing IP positions ahead of potential market entry.
CNS formulation filing trendsAlkem Laboratories' US patent activity in CNS and pharmaceutical formulations
As a large Indian generic pharmaceutical manufacturer, Alkem Laboratories' own US patent filings and ANDA history in the CNS space can signal its competitive positioning and potential counterclaims or design-around strategies in the consolidated lumateperone proceeding. Analysing Alkem's formulation IP activity provides intelligence on the depth of its generic development pipeline.
Generic challenger IP postureAdjacent CNS drug delivery innovation: formulation white space near lumateperone
With core lumateperone formulation claims actively defended by Intra-cellular Therapies, adjacent R&D opportunities may exist in modified-release lumateperone delivery systems, combination therapies, or novel CNS indications not yet covered by the asserted patents. Identifying these white-space areas can guide both innovator pipeline extensions and generic differentiation strategies.
CNS formulation white spaceSimilar ANDA patent infringement cases involving lumateperone and CNS drug formulations
Explore parallel Hatch-Waxman cases in New Jersey District Court involving CAPLYTA® lumateperone patents and comparable multi-defendant ANDA consolidations in the CNS pharmaceutical sector.
What this case signals for the branded pharmaceutical IP landscape
Eight consolidated ANDA actions targeting CAPLYTA® patents indicate coordinated generic entry pressure on a high-value CNS drug franchise.
Coordinated ANDA waves require multi-defendant patent strategy from day one
The consolidation of eight parallel ANDA cases in a single pretrial proceeding signals that Intra-cellular Therapies faces a broad generic challenge front. Branded pharmaceutical patent holders should anticipate coordinated generic filers and structure litigation strategy — including claim construction and expert resources — to address multiple ANDA defendants simultaneously.
Two patents asserted across all defendants raises claim construction stakes
With US12070459B2 and US11980617B2 asserted against eight ANDA filers in a consolidated proceeding, a single claim construction ruling will govern all defendants. This concentrates risk: an adverse Markman outcome affects the entire patent position simultaneously, making early claim mapping and prior art analysis critical for all parties.
Intra-cellular v Alkem — key questions answered
Intra-cellular Therapies asserted two patents: US12070459B2 (application no. US18/504345) and US11980617B2 (application no. US16/981639). Both patents are directed to CAPLYTA® drug products and were asserted against Alkem's proposed generic lumateperone capsules in 10.5 mg, 21 mg, and 42 mg strengths.
The case was closed because it was consolidated with seven other related civil actions — including 3:24-cv-04264, 3:24-cv-08848, 3:24-cv-08850, 3:24-cv-08852, 3:24-cv-08854, 3:24-cv-08855, and 3:24-cv-08856 — for all pretrial purposes. The standalone docket was terminated administratively; litigation against Alkem continues in the consolidated proceeding.
Consolidation merges the Alkem action with seven other ANDA cases into a single pretrial proceeding. This means claim construction, discovery, and scheduling will be managed jointly. A single Markman ruling on US12070459B2 and US11980617B2 will bind all consolidated defendants, concentrating the legal outcome risk across all eight cases simultaneously.
Based on the consolidation order, eight civil actions were merged for pretrial purposes, suggesting at least eight ANDA defendants are challenging the CAPLYTA® lumateperone patents. The specific identities of all eight defendants beyond Alkem Laboratories are not disclosed in the available record for this individual docket.
The products at issue are CAPLYTA® drug products marketed by Intra-cellular Therapies and Alkem's proposed generic lumateperone capsules in three dosage strengths: 10.5 mg, 21 mg, and 42 mg — corresponding to the full commercial dosage range of CAPLYTA® currently on the US market.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.